Q4 2025 · 13F-HR
Euclidean Capital LLCholdings as filed
Filed 2026-02-17 · accession 0001012975-26-000154
$369.5M
Reported value
12
Positions
2025-12-31
Period end
The Brief · Euclidean Capital LLC · Q4 2025
AI · grounded in 13F
Euclidean Capital LLC established a new position in VTV valued at $99.3M. The fund also increased its holdings in VEU by 15.98%. These moves brought the fund's total position count to 12 with total AUM of $369.5M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 922042775 | VEU | VANGUARD INTL EQUITY INDEX F | $220.0M | 59.5% | 2,990,084 | Common | SOLE |
| 922908744 | VTV | VANGUARD INDEX FDS | $99.3M | 26.9% | 520,000 | Common | SOLE |
| 46429B598 | INDA | ISHARES TR | $20.0M | 5.41% | 369,600 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $8.5M | 2.30% | 1,573,761 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $8.1M | 2.19% | 989,410 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $3.3M | 0.89% | 2,627,643 | Common | SOLE |
| 78462F103 | SPY | SPDR S&P 500 ETF TR | $2.8M | 0.76% | 4,104 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $2.8M | 0.75% | 82,234 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $2.0M | 0.55% | 1,307,858 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $2.0M | 0.54% | 87,696 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $722,674 | 0.20% | 1,015,705 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $3,417 | 0.00% | 170,833 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.